Lenalidomide, a novel immunomodulatory drug (IMiD), is a promising therapeutic strategy for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell lymphomas. Biologically, the mechanisms responsible for lenalidomide activity are yet to be clearly defined. Based on preclinical models and early correlative studies conducted in parallel to clinical trials, lenalidomide has been found to enhance natural killer (NK)-and T-cell activity against tumor cells, alter the balance of pro-and anti-inflammatory cytokines in the tumor bed, inhibit angiogenesis, and, to a lesser degree, induce cell cycle arrest and apoptosis in cancer cells. Together, all of these biological effects appear to play a role in the activity observed in CLL or lymphoma patients treated with lenalidomide. Given the effect in NK-and T-cell function, lenalidomide is an alternative strategy to enhance the antitumor activity of monoclonal antibodies (mAbs). Clinical responses have been observed in patients with relapsed/refractory CLL, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) treated with lenalidomide single agent. The favorable toxicity profile and route of administration made the use of lenalidomide an attractive therapy for certain types of patients (i.e. elderly, chemotherapy unfit, etc.). The erratic but serious incidence of tumor lysis syndrome and/or tumor flare reactions provides challenges in the incorporation of lenalidomide in the management of previously untreated CLL or CLL/lymphoma patients with bulky adenopathy. Correlative studies and/or retrospective analysis of lenalidomide-treated patients had identified several biomarkers associated with clinical endpoints in CLL (i.e. changes in tumor necrosis factor alpha [TNF-a] or vascular endothelial growth factor [VEGF] levels) or DLBCL (non-GCB phenotype) patients, but need to be validated. Early studies evaluating the efficacy and toxicity of lenalidomide in combination with rituximab in previously untreated indolent lymphoma are promising and warrant further study. In addition, the evaluation of lenalidomide in the maintenance setting or in combination with other target-specific agents (i.e. proteasome inhibitors) in aggressive lymphomas is being addressed in ongoing clinical trials. In summary, lenalidomide is emerging as a biologically active and novel agent in the treatment of B-cell neoplasms. Future translational and clinical studies will further define the role of lenalidomide in the management of de novo or relapsed/ refractory CLL or B-cell lymphomas and identify the subset of patients most likely to gain clinical benefit.
Introduction
According to this year's published cancer statistics, approximately 74,030 and 14,990 new cases of lymphoma and chronic lymphocytic leukemia (CLL), respectively, will be diagnosed in 2010 [Jemal et al. 2010 ]. In addition, despite current available treatments, 21,530 lymphoma patients and 4390 CLL patients will die this year [Jemal et al. 2010] . Non-Hodgkin's lymphomas (NHLs) are the sixth most common cancer in the United States and depending on sex, the sixth (females) or eighth (males) most common cause of cancerrelated death in the United States [Jemal et al. 2010] .
The use of rituximab in combination with systemic chemotherapy has not only improved the clinical outcome of patients with B-cell lymphomas and CLL, but appears to be changing the biology of relapsed/refractory disease [Martin et al. 2008] . In order to address the challenge of managing relapsed/refractory B-cell malignancies in the rituximab era, it is important to evaluate novel therapeutic strategies targeting key regulatory pathways associated with the development, maintenance and/or progression of such conditions.
Lenalidomide is an immunomodulatory drug (IMiD) derived from thalidomide. Structurally, lenalidomide has one amino and one oxo group in its phthaloyl ring as compared with two oxo groups seen in the chemical structure of thalidomide ( Figure 1 ). Biologically, lenalidomide appears to be 10,000 times more potent and has a better safety profile as compared with its parent compound thalidomide [Teo, 2005] . Biological antitumor effects had been demonstrated in lenalidomide preclinical models and clinical trials representing a wide spectrum of malignancies.
Lenalidomide possess significant anti-tumor activity in various hematological malignancies including: multiple myeloma (MM), myelodysplastic syndrome (MDS), CLL, and NHL. The United States Food and Drug Administration (FDA) approved lenalidomide for the treatment of MM or MDS associated with 5q deletion. In addition, clinically significant antitumor activity has been observed in CLL and various subtypes of B-cell lymphomas. Ongoing clinical studies are seeking to further define the role of lenalidomide in lymphoid malignancies. In our current report, we provide a comprehensive review of laboratory studies aimed at understanding the mechanisms of action of lenalidomide and an update on the clinical studies evaluating lenalidomide in B-cell lymphomas.
Mechanisms of action of lenalidomide in hematological malignancies
While lenalidomide's exact mechanisms of action continue to be a subject of controversy and study, direct cytotoxicity against malignant cells and immunomodulatory effects in endothelial, stromal, and immune cells (T cells, dendritic cells [DCs] , and natural killer [NK] cells) has been demonstrated in preclinical models.
Direct antitumor effects of lenalidomide in hematological malignancies
The direct effects of lenalidomide in cancer cells differ depending on experimental conditions, model tested (cell lines versus mouse models), or disease studied. In MM and MDS preclinical studies, the in vitro exposure of cell lines to lenalidomide results in decreased cell proliferation [Pellagatti et al. 2007; Bartlett et al. 2004] . Similar effects have been demonstrated in lymphoma cell lines [Hernandez-Ilizaliturri et al. 2005] .
The mechanisms by which lenalidomide inhibit the proliferation of malignant cells are yet to be defined. Induction of direct apoptosis following lenalidomide exposure in vitro is inconsistent and cell dependent. Recently, several investigators had demonstrated that lenalidomide might induce cell cycle arrest in MM and lymphoma cell lines [Escoubet-Lozach et al. 2009; Gandhi et al. 2006 ]. Ongoing studies are characterizing the effects of lenalidomide in cell cycle regulatory proteins among different subtypes of hematological malignancies to further characterize its direct antitumor activity.
Immunomodulatory effects of lenalidomide
More consistently, investigators had demonstrated that lenalidomide activates NK cells potentiating the biological activity of monoclonal antibodies (mAbs) in B-cell lymphomas, activate cytotoxic T cells against to directly target malignant cells, alters the cytokine microenvironment in the tumor bed, and inhibit angiogenesis [Zhang et al. 2009; Reddy et al. 2008; Wu et al. 2008; Hernandez-Ilizaliturri et al. 2005; LeBlanc et al. 2004 ].
In recent years, scientists have become interested in characterizing the interactions between cancer cells and the tumor microenvironment, in particular, the production of cytokines by accessory cells (i.e. stromal, DC, NK and endothelial cells) that may sustain and promote tumor growth. Cytokines can influence gene activation, growth, cell differentiation, functional cell surface molecule expression, and cellular effector function. The balance between pro-and antiinflammatory cytokines may affect the host responses against malignant cells. In vitro exposure to lenalidomide has been shown to inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-a), interleukin 1 (IL-1), interleukin 6 (IL-6), and interleukin 12 (IL-12). In addition, lenalidomide drug exposure has been associated with increased levels of the anti-inflammatory cytokine interleukin 10 (IL-10) in human peripheral blood mononuclear cells (PBMCs) Corral and Kaplan, 1999] . The capacity of lenalidomide to decrease TNF-a secretion is up to 50,000 times higher than thalidomide [Corral and Kaplan, 1999; Muller et al. 1999] . Elevated TNF-a levels had been implicated in the pathogenesis of various hematological malignancies (CLL and MM) and or ineffective hematopoiesis as seen in MDS [Symeonidis et al. 1991] .
In vitro, lenalidomide downregulates the production of IL-6 by bone marrow stromal cells leading to apoptosis and a decrease in cell proliferation of MM cells [Breitkreutz et al. 2008; Lichtenstein et al. 1995] .
Correlative studies reported by Ferrajoli and colleagues conducted in relapsed/refractory CLL patients treated with lenalidomide single agent have shown a decrease in TNF-a levels as early as 7 days after treatment initiation and direct correlation between changes in TNF-a levels and antitumor activity [Ferrajoli et al. 2008] .
While the precise mechanism that mediates lenalidomide effects in TNF-a levels is unknown, it may be similar to thalidomide, that had been shown to promote TNF-a-mRNA degradation in monocytes [Moreira et al. 1993 ].
In addition to changes in the cytokine milieu, lenalidomide has been shown to affect the function of immune effector cells. In vitro studies reported by LeBlanc and colleagues suggest that lenalidomide costimulates T cells in the presence of antigen-presenting cells (APCs) via the B7-CD28 costimulatory pathway [LeBlanc et al. 2004 ]. Lenalidomide-mediated T-cell costimulation leads to an increase in interferon gamma (INF-g) and interleukin 2 (IL-2) production responsible for (1) autocrine T-cell proliferation, (2) paracrine NK-cell activation, and (3) increase in mAb (rituximab or trastuzumab)-mediated antibody-dependent cellular cytotoxicity (ADCC) [Reddy et al. 2008; Wu et al. 2008 ]. Modulation of NK-cell function had been associated with the antitumor activity observed in MDS, MM, and CLL treated with lenalidomide.
Recently, Ramsay and colleagues demonstrated that lenalidomide modulates T-cell responses in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Using primary tumor cells and autologous T-cell isolated from FL or DLBCL patients, this group of investigators demonstrated that lenalidomide repaired F-actin-mediated T-cell immune synapse and downstream signaling. Moreover, ex vivo exposure of primary tumor cells and T cells to lenalidomide restored T-cell function against lymphoma cells [Ramsay et al. 2009 ].
Finally, lenalidomide possess anti-angiogenesis properties. In preclinical studies, exposure of MM cells to lenalidomide results in decreased production of vascular endothelial growth factor (VEGF) [Gupta et al. 2001] . Our group of investigators demonstrated that in vivo treatment of lymphoma bearing severe combined immunodeficiency (SCID) mice with lenalidomide resulted in decreased angiogenesis as determined by immunohistochemistry (IHC) [Reddy et al. 2008] .
Angiogenesis inhibition had been demonstrated in bone marrow samples of -5q MDS patients treated with lenalidomide single agent and the degree of angiogenesis inhibition correlated with clinical response [Kotla et al. 2009] . A decrease in VEGF levels was also observed in CLL treated with lenalidomide [Ferrajoli et al. 2008 ].
Together, the data generated by several groups of investigators suggest that lenalidomide targets cancer cells directly by altering the cell cycle or apoptosis and indirectly by altering the immunological synapsis or the tumor microenvironment. Despite the advances achieved, the exact mechanisms responsible for the antitumor activity of lenalidomide observed in patients with MDS or lymphoid malignancies remains undetermined. It is possible that the primary mechanisms of action of lenalidomide could be disease specific.
Ongoing translational studies are aiming to further characterize the biological effects of lenalidomide in each subtype of lymphoid malignancies in an attempt to optimize its antitumor activity and to identify biomarkers of response than can be used to identify patients that are most likely to derive a clinical benefit from this novel agent.
Clinical studies in chronic lymphocytic leukemia
The clinical activity of lenalidomide in relapsed/ refractory CLL had been evaluated in two prospective phase II studies (Table 1) . Chanan-Khan and colleagues reported the first clinical study evaluating the safety and efficacy of lenalidomide administered orally (p.o.) as monotherapy at 25 mg daily for 21 days every 28 days [Chanan-Khan et al. 2006 ]. Allopurinol was administered for the prevention of tumor lysis syndrome (TLS). A total of 45 patients with relapsed/ refractory CLL were enrolled in the study, but only 29 patients were assessable for response. The median age of the patient in the study was 64 years, the median number of prior therapies was three (range 110), and 51% of the patients were considered fludarabine refractory.
Response was assessed using the revised 1996 National Cancer Institute (NCI) Working Group guidelines [Cheson et al. 1996 [Sher et al. 2010 ].
The second clinical study was conducted at the MD Anderson Cancer Center and reported by Ferrajoli and colleagues [Ferrajoli et al. 2008] . A total of 44 relapsed/refractory advance CLL patients (Rai stage 3 or 4) were enrolled and treated with lenalidomide administered at a starting dose of 10 mg p.o. daily for 28 days until disease progression or unacceptable toxicity. The dose of lenalidomide was subsequently escalated, if tolerated, by 5 mg increments. The median age of entire group was 64 years and the median number of prior treatments was five (range 115). Using similar response criteria, antitumor activity was observed in 32% of the patients. Partial remission (PR) was observed in 25% of the patients, one patient achieved a nodular PR and three patients achieved a CR. Time to best response was mostly observed after 6 or 9 months of therapy.
Hematological grade 34 toxicities were the most common adverse events, grade 34 neutropenia and thrombocytopenia was observed in 41% and 16% of the courses administered to the patients, respectively. Grade 12 or 34 tumor flare reaction was observed in 10% and 2% of the courses, respectively. While the occurrence of tumor flare reaction did not correlate to clinical activity, it was more frequently observed in patients with higher tumor burden [Ferrajoli et al. 2008] .
While activity was observed in heavily pre-treated CLL patients, the follow-up period in both studies is short and mature information regarding progression-free survival (PFS) and overall survival (OS) is not available.
The use of lenalidomide in previously untreated CLL was halted due to the erratic but severe incidence of TLS observed. Currently, studies are evaluating low-dose lenalidomide in highly selected untreated CLL patients to further define the role of lenalidomide in the front-line setting. Outside clinical studies, the use of lenalidomide in previously untreated CLL patients is contraindicated.
Clinical studies in non-Hodgkin's lymphoma
Lenalidomide studies in diffuse large and transformed B-cell non-Hodgkin's lymphoma Several studies evaluating the antitumor activity of lenalidomide have been conducted in different types of NHL ( [Czuczman et al. 2008 ]. Again, grade 3 or 4 neutropenia (32%), thrombocytopenia (15%), asthenia (8%), and anemia (7%) were the most common events observed. The results of these two clinical studies confirm the activity of lenalidomide in heavily pretreated patients with relapsed or refractory DLBCL with manageable side effects.
Scientific interests are focused on identifying subsets of lymphoma patients most likely to benefit from lenalidomide therapy. We retrospectively evaluated differences in clinical outcomes for patients with germinal center B-cell-like (GCB) versus non-GCB DLBCL, treated with salvage lenalidomide at four academic institutions. The study included 40 patients with relapsed/refractory DLBCL treated under the NHL-003 study or with lenalidomide approved for off-label use.
Patients were classified as GCB (n ¼ 23) or non-GCB (n ¼ 17) DLBCL subgroups utilizing the Han's algorithm [Hans et al. 2004 ]. A significant difference in clinical response to lenalidomide was observed: ORR was 53% for non-GCB patients versus 8.7% for GCB patients (p ¼ 0.006); CR rate was 23.6% in non-GCB patients versus 4.34% in GCB patients. The PFS was 6.23 months in non-GBC patients versus 1.7 months in GCB patients (p ¼ 0.004). No difference in OS was observed between GCB and non-GCB DLBCL patients. Our data suggest that the two major subgroups of patients with DLBCL (GCB versus non-GCB) have different antitumor responsiveness to lenalidomide in the relapsed/refractory setting . A large international trial is actively enrolling relapsed/refractory DLBCL patients failing high-dose chemotherapy and autologous stem cell support (HDC-ASCS) or nontransplant eligible in an attempt to prospectively validate our retrospective observations.
Lenalidomide studies in indolent B-cell lymphoma
Lenalidomide has also been studied in patients with relapsed/refractory indolent B-cell lymphoma [Witzig et al. 2009 ]. Witzig and colleagues prospectively evaluated the safety and efficacy of lenalidomide monotherapy in 43 patients with relapsed/refractory grade 1 or 2 FL (51%), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL). The median age of the patients was 63 years and the median number of prior treatment regimens was three.
Patients received lenalidomide at 25 mg p.o. daily on days 121 every 28 days for 52 weeks or until disease progression or unacceptable toxicity. In this patient population, the ORR to lenalidomide was 23%, with three patients achieving a CR (n ¼ 2) or unconfirmed CR (CRu, n ¼ 1) and seven patients a PR. Activity was observed in patients with FL and SLL [Witzig et al. 2009 ].
The median time to antitumor response was 3.6 months (1.74.2 months) and the median PFS for all patients was 4.4 months (95% confidence interval [CI], 2.510.4 months).
The type and incidence of adverse events were similar to prior CLL or lymphoma studies (i.e. hematological toxicity).
Based on preclinical studies demonstrating synergistic activity between rituximab and lenalidomide in lymphoma models, several investigators are evaluating the efficacy and tolerability of lenalidomide in combination with rituximab in indolent lymphomas.
Recently, Fowler and colleagues reported the preliminary results of lenalidomide in combination with rituximab in stage III or IV newly diagnosed indolent lymphoma patients. The preliminary report included 48 indolent lymphomas including 30 FL patients that received rituximab at 325 mg/m 2 on day 1 and lenalidomide 20 mg/ day p.o. on days 121 every 28 days for up to six cycles. The ORR of the entire cohort of patients was 86% and 93% for FL patients. CR was observed in 79% of the patients and in 86% of the FL patients. The PFS at a median follow up of 20 months is 91% [Fowler et al. 2010] .
Adverse events were similar to those observed in lenalidomide single-agent studies. Of interest, no significant tumor flare reactions were observed. Currently, the study continues to enroll patients and the final results of the study with mature follow-up data are eagerly awaited.
The Cancer and Leukemia Group B (CALGB) is conducting a prospective randomized phase II study evaluating the safety and efficacy of lenali-domide±rituximab in relapsed/refractory indolent lymphoma patients previously treated with rituximab-based chemo-immunotherapy.
Lenalidomide studies in mantle cell lymphoma
The NHL-003 study also evaluated the safety and efficacy of lenalidomide in relapsed/refractory mantle cell lymphoma (MCL). Zinzani and colleagues reported the preliminary results of lenalidomide monotherapy in 39 patients with relapsed or refractory MCL enrolled in the NHL-003 study. The median age of the patients was 66 years (range 3382), most of them males (74%), and the median number of prior treatments was three. Lenalidomide therapy resulted in an ORR of 41%, including five CR (13%). Disease stabilization was observed in 26% of the patients. As noted in prior clinical trials with lenalidomide, were grade 3 or 4 neutropenia (51%) and thrombocytopenia (25%) ].
Investigators at the MD Anderson Cancer Center evaluated the combination of lenalidomide and rituximab in MCL patients. Wang Ongoing clinical studies are evaluating the antitumor activity of lenalidomide as maintenance therapy following HDC-ASCS in de novo MCL. In previously untreated MCL patients, noneligible for HDC-ASCT, lenalidomide is been studied in combination with rituximab and bendamustine (Nordic Lymphoma Group Study MCL-4) or as maintenance following rituximab-based chemotherapy (RENEW study, NCT01021423) or rituximabbendamustine induction (planned Intergroup study). In addition, lenalidomide is being evaluated in combination with rituxi-mab±bortezomib or bendamustine in the relapsed/refractory setting.
Lenalidomide studies in other histologies
Early clinical trials had evaluated lenalidomide in other less-common forms of relapsed/refractory lymphomas including Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL). Fehniger and colleagues evaluated the activity of lenalidomide in 38 patients with relapsed/refractory HL. The dose schedule administered was similar to the NHL-002 and NHL-003 studies. Of the 35 patients treated with lenalidomide, 17% achieved a radiographic response (CR or PR) and 17% had a cytostatic response (SD). The median duration of response was 4 months and the toxicity profile encounter was similar to previous studies with lenalidomide [Fehniger et al. 2009 ].
Lenalidomide is being evaluated in patients with T-cell lymphomas. Early results from two prospective studies evaluating the activity of lenalidomide in CTCL or PTCL were reported at the annual meeting of the American Society of Hematology. Querfeld and colleagues are evaluating the antitumor activity of lenalidomide in patients with CTCL and found early encouraging responses [Querfeld et al. 2005 ]. In addition, Reiman and colleagues are evaluating the activity of single-agent lenalidomide in patients with relapsed/refractory PTCL. In this Canadian multicenter study, patients are being treated with lenalidomide at 25 mg on days 121 every 28 days until disease progression or unacceptable toxicity. The investigators presented initial results on 10 PTCL patients and found a PR rate of 44% (4/9 patients) and disease stabilization in 56% [Reiman et al. 2007 ]. While the early results from these two studies are promising, further patient recruitment and follow up is necessary to allow better interpretation of the data.
In summary, lenalidomide is emerging as a promising therapeutic option for patients with relapsed/refractory CLL and various subtypes of B-cell lymphomas (FL, DLBCL, and MCL).
The clinical activity observed in the relapsed/ refractory setting and the acceptable toxicity profile support the use of lenalidomide in patients with limited performance status, and in those patients seeking to avoid adverse events associated with systemic chemotherapy. In the frontline setting the activity observed in FL treated with rituximablenalidomide is encouraging and may result in an effective therapeutic option for FL in the near future. Ongoing and future translational and clinical studies will provide insightful information that will guide physicians in the optimal use of lenalidomide as a single agent or in combination with other biological/target specific agents or chemotherapy regimens (i.e. R þ CHOP). Moreover, correlative studies with lenalidomide have the potential to aid in the selection of patients based on biomarkers that are most likely to benefit from lenalidomide-based therapies.
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